Navigation Links
Clinical trial launches to see whether vitamin D helps treat multiple sclerosis
Date:4/19/2012

New York Doctors at several centers across the U.S. are recruiting people who have multiple sclerosis (MS) to determine the effectiveness of high-dose vitamin D supplements for reducing MS disease activity. The vitamins would be added to standard therapy with glatiramer acetate (Copaxone, Teva Pharmaceutical Industries). The study, funded by the National Multiple Sclerosis Society, is being led by Ellen Mowry, MD, MCR, at Johns Hopkins University in Baltimore. Other cities with centers recruiting participants include Portland, St. Louis, and San Francisco, and additional centers are being established.

A number of genetic and environmental factors influence whether a person will get MS. These factors may also impact the severity of the disease. Mounting evidence has been pointing to a reduced level of vitamin D in the blood as a risk factor for developing MS. In lab mice, vitamin D can reduce the effects of EAE, an MS-like disease, and growing evidence suggests it is time to test whether vitamin D can provide benefits to people who have MS.

Investigators are seeking 172 clinical trial participants between the ages of 18 and 50, who have been diagnosed with the relapsing-remitting form of MS. More details on the enrollment criteria are available at: http://www.clinicaltrials.gov/ct2/show/NCT01490502.

Participants will begin standard Copaxone treatment daily and will be randomly assigned to take the current recommended daily allowance of vitamin D or a high dose. The primary goal of the study is to determine whether vitamin D can reduce the proportion of people who experience a relapse. Other outcomes being studied include relapse rates, quality of life, brain tissue volume, disability progression, and safety.


'/>"/>

Contact: Arney Rosenblat
arney.rosenblat@nmss.org
212-476-0436
National Multiple Sclerosis Society
Source:Eurekalert

Page: 1

Related biology news :

1. A new journal where molecular biology meets clinical research
2. Self-assembling nano-fiber gel delivers high concentrations of clinically approved drugs
3. Biochemistry of human physiology in health and disease is focus of updated clinical text
4. New book helps medical students master clinical skills
5. In just 5 years, gene discovery to clinical trial of potential treatment
6. Far-reaching genetics topics to be addressed: 2009 Annual Clinical Genetics Meeting, March 25-29
7. Genome Medicine: Bridging the gap between research and clinical practice
8. 3 new informatics pilot projects to aid clinical and translational scientists nationwide
9. TGen Clinical Research Services at Scottsdale Healthcare and Mayo Clinic study new cancer drug
10. ABC publishes monograph on scientific and clinical research of Sinupret
11. Researchers win award for best clinical paper in orthopedic physical therapy
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/6/2015)... Apr. 6, 2015 NXT-ID, Inc. (NASDAQ: ... authentication company focused on the growing mobile commerce ... patent 62/143028 for MINIATURE, MULTI-PURPOSE ANTENNA ... NXT-ID introduces a new revolutionary method ... surrounds the use of miniature antenna modules for ...
(Date:4/2/2015)... , April 2, 2015 At its 2015 ... Lake City , the American College of Medical ... new directors to its Board.  Members of the ACMG ... and for forming and advancing its policies and programs. ... profession. "It,s an eventful time in medical ...
(Date:4/2/2015)... Sweden , April 2, 2015 ... its touch fingerprint sensor FPC1025 from the distributor World ... will commence during Q2 2015 although the major part ... The sensors will be used by smartphone manufacturers in ... 110 MSEK is included in the communicated revenue guidance ...
Breaking Biology News(10 mins):NXT-ID Patents Miniature, Low Power Wireless Magnetic Stripe 2NXT-ID Patents Miniature, Low Power Wireless Magnetic Stripe 3NXT-ID Patents Miniature, Low Power Wireless Magnetic Stripe 4American College of Medical Genetics and Genomics Announces New Board Members: Dr. Louanne Hudgins is ACMG President-Elect 2American College of Medical Genetics and Genomics Announces New Board Members: Dr. Louanne Hudgins is ACMG President-Elect 3American College of Medical Genetics and Genomics Announces New Board Members: Dr. Louanne Hudgins is ACMG President-Elect 4American College of Medical Genetics and Genomics Announces New Board Members: Dr. Louanne Hudgins is ACMG President-Elect 5American College of Medical Genetics and Genomics Announces New Board Members: Dr. Louanne Hudgins is ACMG President-Elect 6American College of Medical Genetics and Genomics Announces New Board Members: Dr. Louanne Hudgins is ACMG President-Elect 7American College of Medical Genetics and Genomics Announces New Board Members: Dr. Louanne Hudgins is ACMG President-Elect 8Fingerprint Cards Receives Touch Fingerprint Sensor Order of SEK 110 Million 2
... Eight supply chain professionals were elected in June by the ... the seven existing members of SCC,s board. Newly elected board members, ... as follows: , , , , ... Hewlett Packard , Jane Barrett, Research ...
... generation biofuels made from inedible plant material, including ... numerous scientific studies have shown them to be ... transportation needs. However, before we can begin to ... numerous barriers must be overcome, starting with finding ...
... disorders are a global problem and represent one of the ... are some 500 million people suffering from mental disorders, and ... the leading causes of disease burden. What makes the situation ... is expected to grow for a variety of reasons: an ...
Cached Biology News:New technique can fast-track better ionic liquids for biomass pre-treatments 2New technique can fast-track better ionic liquids for biomass pre-treatments 3New technique can fast-track better ionic liquids for biomass pre-treatments 422nd Congress of the European College of Neuropsychopharmacology, Sept. 12-16, 2009, Turkey 222nd Congress of the European College of Neuropsychopharmacology, Sept. 12-16, 2009, Turkey 322nd Congress of the European College of Neuropsychopharmacology, Sept. 12-16, 2009, Turkey 422nd Congress of the European College of Neuropsychopharmacology, Sept. 12-16, 2009, Turkey 522nd Congress of the European College of Neuropsychopharmacology, Sept. 12-16, 2009, Turkey 622nd Congress of the European College of Neuropsychopharmacology, Sept. 12-16, 2009, Turkey 722nd Congress of the European College of Neuropsychopharmacology, Sept. 12-16, 2009, Turkey 8
(Date:5/21/2015)... 2015 Specialty Pharmacy Times has ... admitted to BPA Worldwide as a business publication ... audience data for Specialty Pharmacy Times based on ... becoming a member of BPA Worldwide, Specialty Pharmacy ... clients with the most reliable, unequaled data,” said ...
(Date:5/21/2015)... NOVATO, Calif. , May 21, 2015 /PRNewswire-USNewswire/ ... Orrin Hatch (R-UT) and Amy ... Product Extensions Now Accelerating Cures & Treatments, or ... 150 rare disease patient advocacy organizations, this bipartisan ... effective, and affordable medicines to rare disease patients ...
(Date:5/21/2015)... 21, 2015  CytRx Corporation (NASDAQ: CYTR ... in oncology, today announced positive updated results from ... for the treatment of unresectable glioblastoma multiforme (GBM), ... multisite trial is designed to investigate the preliminary ... tumors have progressed following prior treatment with surgery, ...
(Date:5/21/2015)... 2015 Veolia’s environmental monitoring technology ... American distribution agreement with VWR to distribute TECTA™ ... more than 160 years of experience, VWR, a ... laboratory and production facilities, has cultivated a value ... services to enable science. Endetec’s TECTA™ B16, ...
Breaking Biology Technology:Specialty Pharmacy Times Joins BPA Worldwide 2Advocates Cheer Senate Leaders for Introducing Bipartisan Bill to Increase Number of Rare Disease Treatments 2CytRx Reports Positive Updated Phase 2 Aldoxorubicin Clinical Trial Results in Glioblastoma Multiforme (Brain Cancer) 2CytRx Reports Positive Updated Phase 2 Aldoxorubicin Clinical Trial Results in Glioblastoma Multiforme (Brain Cancer) 3CytRx Reports Positive Updated Phase 2 Aldoxorubicin Clinical Trial Results in Glioblastoma Multiforme (Brain Cancer) 4CytRx Reports Positive Updated Phase 2 Aldoxorubicin Clinical Trial Results in Glioblastoma Multiforme (Brain Cancer) 5CytRx Reports Positive Updated Phase 2 Aldoxorubicin Clinical Trial Results in Glioblastoma Multiforme (Brain Cancer) 6CytRx Reports Positive Updated Phase 2 Aldoxorubicin Clinical Trial Results in Glioblastoma Multiforme (Brain Cancer) 7Veolia’s TECTA™ B16 Instrument for E. Coli Detection is Offered Exclusively Through VWR 2
... & Seidelmann Subspecialty,Radiology (F&S) has added additional ... appointment of Richard Dyke as senior vice ... Dyke will be responsible for new client,acquisition ... business,development through industry partner channels, strategic marketing, ...
... 13 PharmAthene, Inc.,(NYSE Alternext US: PIP), a ... threats, today reported,financial and operational results for the ... For the third quarter of 2008, PharmAthene ... in the same period of 2007. For the ...
... SPEX ) reported a net loss for the ... million ($0.12 per share) and $4.8 million,($0.34 per share), ... commercialization of Naturlose as a treatment for Type,2 diabetes ... ended,September 30, 2008, compared to approximately $4.5 million for ...
Cached Biology Technology:Franklin & Seidelmann Adds Richard Dyke to Senior Management Team as Senior VP, Sales/Marketing 2Pharmathene Reports Third Quarter 2008 Financial and Operational Results 2Pharmathene Reports Third Quarter 2008 Financial and Operational Results 3Pharmathene Reports Third Quarter 2008 Financial and Operational Results 4Pharmathene Reports Third Quarter 2008 Financial and Operational Results 5Pharmathene Reports Third Quarter 2008 Financial and Operational Results 6Pharmathene Reports Third Quarter 2008 Financial and Operational Results 7Spherix Reports 3rd Quarter Earnings 2
... The H2OBIT is a fully licensed, high ... simultaneous processing of up to 24 microplates. This ... 384-well plates. ,A robotic arm rapidly transfers ... resulting in temperature ramping times that are considerably ...
... Rabbit polyclonal to Dideoxycytidine Dideoxycytidine is ... be effective in inhibiting retroviral activity. ... BSA. Specificity: The specificity of ... ratio of the moles of ddC to moles ...
... MSC series of Class II Biological ... and certification to the world's highest ... that the cabinets cannot be adjusted ... lighting, low noise and arm rest ...
... HM-4000 Multidizer is designed with a ... orbital, rotating - all in one unit. ... Two independently operating compartments allow for hybridization ... or motion , The upper chamber ...
Biology Products: